---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105023"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:42:18.863959+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alector Q2 net loss $30.5M; cash $307.3M; Phase 3 latozinemab data mid-Q4

## Summary
- Net loss $30.5M ($0.30/sh) vs $38.7M ($0.40/sh) in Q2 2024; revenue $7.9M down from $15.1M.
- Cash, cash equivalents, and investments $307.3M, providing runway into H2 2027.
- On track to report topline data from INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN by mid-Q4 2025.
- Guidance updated: collaboration revenue $13-18M, R&D expenses $130-140M, G&A $55-65M for FY2025.
- Neil Berkley appointed interim CFO; USPTO issued patent for latozinemab treatment method.

## SEC filing metadata
- accession: 0000950170-25-105023
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017025105023/0000950170-25-105023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017025105023/alec-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105023
- JSON: https://secwatch.observer/filing/0000950170-25-105023.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.